LIfT BioSciences Appoints World-Leading Cancer Immunotherapy Experts to Scientific Advisory Board Ahead of First-in-Human IMAN Trials

Members include Nobel laureate James P. Allison, Padmanee Sharma, Taha Merghoub, and Kingston Mills, who are all globally renowned experts in cancer im...

May 08, 2026 | Friday | News
BriaCell Therapeutics Corp. Expands Phase 3 Bria-ABC Breast Cancer Trial with Addition of NYU Langone Health’s Perlmutter Cancer Center

BriaCell Therapeutics Corp. a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care is pleased to announce the a...

May 08, 2026 | Friday | News
ArriVent BioPharma Secures FDA IND Clearance for Dual-Target ADC ARR-002 in Ovarian and Endometrial Cancers

Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approaches Pha...

May 08, 2026 | Friday | News
FreeMind Investments and Daewoong Pharmaceutical Invest in General Proximity to Advance Induced Proximity Therapeutics

FreeMind Investments (FMI), a venture capital fund launched in partnership between FreeMind Group and Daewoong Pharmaceutical Co., Ltd., announced its in...

May 06, 2026 | Wednesday | News
UCB to Acquire Candid Therapeutics in Up to $2.2 Billion Deal to Expand Next-Generation Immunology Portfolio

Deal builds upon UCB’s position as a leader in immunology innovation and expands capabilities in next-generation biologics with potential for i...

May 05, 2026 | Tuesday | News
Advancing Precision Radiotherapeutics for Hard-to-Treat CNS Cancers

  Central nervous system (CNS) cancers remain among the most difficult diseases to treat in oncology, with limited therapeutic options, complex deliv...

May 04, 2026 | Monday | Interaction
Anixa Biosciences Secures Mexico Patent for Breast Cancer Vaccine, Extending IP Protection to 2040

Expands global intellectual property coverage in markets with greater late-stage breast cancerdiagnoses and higher triple-negative breast cancer incidenc...

May 01, 2026 | Friday | News
Crown Bioscience Partners with Turbine to Advance Translational Oncology with Integrated In Silico and Organoid Platforms

 Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, announced a strategic partnership with Turbine, a ...

April 23, 2026 | Thursday | News
Evaxion’s EVX-01 Shows Record 86% Immune Response Rate in Phase 2 Personalized Cancer Vaccine Study

New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response...

April 20, 2026 | Monday | News
Telix Advances First Radiopharmaceutical Therapy Into Phase III For Glioblastoma Treatment

Telix Pharmaceuticals Limited announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s pivota...

April 16, 2026 | Thursday | News
BioNTech’s Trastuzumab Pamirtecan Shows Strong Phase 2 Efficacy in HER2-Expressing Endometrial Cancer

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-...

April 14, 2026 | Tuesday | News
NexTel Medical Corp Initiates First Phase of Global Rollout for Exosome-Based Cancer Screening Test

NexTel Medical Corp f/k/a Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery syste...

April 09, 2026 | Thursday | News
Curanex Pharmaceuticals, Inc. Expands Pipeline to Target Cancer Cachexia, Addressing Major Oncology Supportive-Care Gap

Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (&...

April 07, 2026 | Tuesday | News
CellCarta And Pillar Biosciences Partner To Accelerate Biomarker Driven Oncology Trials

The partnership pairs Pillar's portfolio of oncoReveal® kitted NGS panels with CellCarta's global laboratory network and biomarker expertise to reduc...

April 03, 2026 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close